FDA Approves Bristol’s Opdivo With Chemotherapy for Lung Cancer

FDA approves Opdivo (nivolumab) with chemotherapy as neoadjuvant treatment for certain adults with resectable non-small cell lung cancer, Bristol Myers Squibb says.

• Approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer

NOTE

• Bristol-Myers Squibb Co. fell 0.2% in postmarket trading to $69.25 as of 5:45 p.m. New York time
  • The average 12-month price target of $72.90 is 5.3% above the current price
  • 15 buys, 9 holds, 0 sells

To view the source of this information, click here

To contact the reporter on this story:
Jim Silver in New York at jsilver@bloomberg.net

To contact the ...